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Abstract
Background: Tolvaptan (TLV) is a useful diuretic for acute decompensated heart failure 
(ADHF) with fluid overload, but its clinical response varies between patients. The aim of this 
study is to investigate whether plasma TLV concentrations correlate with the urine volume.
Methods: ADHF inpatients with evidence of fluid overload and total urine volume < 1,500 mL  
24 h after initial intravenous administration of 40 mg furosemide were included in the study. 
On days 1–7, 7.5 mg oral TLV was added. The plasma TLV concentration, plasma renin ac-
tivity (PRA), and plasma aldosterone concentration (PAC) were measured on days 1, 3 and 7.
Results: In the 52 patients who completed the protocol, the TLV concentration increased 
significantly from 67.6 ± 30.1 ng/mL on day 1 to 98.3 ± 39.6 ng/mL on day 3 to 144.8 ± 
± 44.2 ng/mL on day 7, and the TLV concentration correlated with total urine volume on 
days 3 and 7 (r = 0.392, p < 0.01; r = 0.639, p < 0.001, respectively) but not on day 1. The 
urine volume correlated inversely with PRA and PAC (r = −0.618, p < 0.05; r = −0.547, 
p < 0.05, respectively).
Conclusions: Plasma TLV concentrations correlated with the urine volume in late phase 
of treatment but not in early phase, which suggests that the effect of TLV may possibly be in-
hibited by renin–angiotensin–aldosterone system activity. (Cardiol J 2016; 23, 5: 497–504)
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Introduction
Tolvaptan (TLV), a selective V2-vasopressin 
receptor antagonist, is known for its excellent 
diuretic effect, and in Japan, it has been essential 
for intensive treatment of patients hospitalized for 
acute decompensated heart failure (ADHF) with 
fluid overload [1–9]. Since its approval for clinical 
use, we have noticed that the response to TLV var-
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action has been discussed, which may be affected 
by renal function, anemia and low cardiac output. 
However, TLV is an oral drug and thus might be 
affected by intestinal absorption, and heart failure 
patients for whom this oral drug is indicated usually 
have fluid overload and digestive system swelling. 
What follows, differences in patients’ absorption 
of TLV might be responsible for differences in the 
clinical response to TLV, even though the dosages 
and patients’ medical conditions are the same. 
When we discuss the clinical responses to TLV, we 
must understand the relation between a patient’s 
plasma TLV concentration and patient’s clinical 
response. However, to our knowledge, this ques-
tion has been explored in only a few patients with 
ADHF and fluid overload [10]. Thus, the purpose 
of the present study was to determine whether 
the plasma concentration of TLV differs between 
the early phase of treatment and the late phase, 
and whether the plasma TLV concentration is as-
sociated with urine volume in ADHF patients with 
evidence of fluid overload.
Methods
Patients
Consecutive patients who were admitted to 
our hospital between April 1, 2014 and March 31, 
2015 for worsening congestive heart failure requir-
ing intensive treatment were screened for partici-
pation in our study. Patients considered eligible for 
the study were men and women over 20 years of 
age with evidence of fluid overload at the time 
of screening, having orthopnea and edema of the 
extremities and jugular venous distention defined 
as jugular venous pressure (JVP) > 10 cm H2O, and 
at least rales at the base of the lungs (Killip class 2 
or 3). We excluded patients with acute myocardial 
infarction at the time of admission; patients using 
any inotropic agent, cardiac mechanical support 
and/or ventilation including non-invasive positive 
pressure ventilation; patients on hemofiltration or 
dialysis; those with pulmonary hypertension due to 
pre-capillary occlusion; those with systolic blood 
pressure < 100 mm Hg upon admission; those 
with an estimated glomerular filtration rate (eGFR) 
< 60 mL/min/1.73 m2; those with hemoglobin 
< 10.0 g/mL or a serum sodium concentration 
> 146 mEq/L; and those from whom we did not 
obtain informed consent.
Study design
Patients were screened within 6 h of hospitali-
zation, and eligible patients were given 40 mg furo-
semide intravenously until the first morning (day 0). 
Patients whose 24-h cumulative urine volume 
was > 1,500 mL were excluded. For patients not 
excluded, 7.5 mg TLV was added to the 40 mg furo-
semide starting on the next morning (day 1) and 
continuing for 7 days (from day 1 to day 7) (Fig. 1). 
Oral medications which the patients had been 
taking before hospitalization, including digoxin, 
any angiotensin-converting enzyme inhibitor, 
angiotensin II receptor blocker, beta-blocker, and 
nitrate, were continued for at least 7 days at the 
discretion of the attending physician. Patients 
treated with any inotropic agent or carperitide 
(recombinant human natriuretic peptide) and any 
diuretic, except intravenous furosemide, were 
excluded for the duration of the study. During the 
TLV administration period, total daily fluid intake 
was adjusted to equal the 24-h urine volume on the 
prior day minus 500 mL.Patients whose symptoms 
or signs of fluid overload disappeared in fewer 
7 days are dropped from this protocol.
Patients’ symptoms, graded on a visual analog 
scale from 0 (worst ever) to 10 (no symptoms); 
extremity edema, graded as 0 (none) to 4 (severe); 
jugular venous distention, hepatomegaly and/or 
hepatojugular reflux were assessed daily by pa-
tients’ attending physicians after blood sampling. 
Blood samples for measurement of plasma renin 
activity (PRA), plasma aldosterone concentration 
(PAC) and blood concentration of noradrenaline 
were drawn at 8:00 AM on days 1, 3 and 7, and 
patients were required to rest supine on a bed for 
30 min before samples were drawn. Samples were 
Figure 1. Schematic representation of the study proto-
col; ADHF — acute decompensated heart failure.
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drawn for the plasma TLV concentration exactly 
4 h after oral administration of TLV. Blood samples 
were collected in heparinized vacuum tubes, gently 
mixed, and then immediately centrifuged at 4°C 
for 15 min at 2,000 g for plasma separation. The 
plasma was stored at −20°C or below until assay. 
The plasma TLV concentration was determined 
by means of a validated high-performance liq-
uid chromatography tandem mass spectrometry 
method at Toray Research Center, Inc. Details 
have been described previously [11]. The safety 
of TLV administration in each case was based on 
an assessment of the patient’s physical signs and 
symptoms, laboratory tests, and vital signs. The 
study protocol was stopped if a patient’s attend-
ing physician advised accordingly. This study was 
approved by the institutional review board and 
Ethics Committee of Nihon University Itabashi 
Hospital, and it was conducted in accordance with 
the principals outlined in the Declaration of Hel-
sinki. Written informed consent was obtained from 
all participants.
Statistical analysis
Continuous variables are expressed as mean ± 
standard deviation (SD), and categorical variables 
as median [Q1–Q3] values or number (percentage) 
of patients. Differences in continuous variables 
were analyzed by means of paired Student’s 
t-test, and differences in categorical variables were 
analyzed by c2 test. Relations between variables 
were assessed by Pearson’s product-moment cor-
relation coefficient. All statistical analyses were 
carried out with SAS (version 9.0; SAS Institute 




Two hundred eighty-six patients met the 
initial inclusion criteria and were given 40 mg 
furosemide intravenously until the first morning 
(day 0). Ninety-two patients with a cumulative 
24-h urine volume of less than 1,500 mL after the 
administration of furosemide were given 7.5 mg 
of oral TLV starting on day 1. Forty patients were 
dropped from the study (36 patients in whom the 
symptoms fluid overload disappeared in fewer than 
7 days and 4 patients in whom the serum sodium 
level increased to more than 146 mEq/mL). Thus, 
52 patients completed the study protocol (Fig. 2).
Mean age of the 52 patients who completed 
the protocol was 66.4 ± 11.8 years, the male/fe-
male ratio was 31/21, mean systolic blood pressure 
amounted to 121 ± 15 mm Hg and heart rate to 
84 ± 18 bmp. Nine (17%) patients had ischemic 
heart disease, and 6 (12%) had atrial fibrillation. 
Forty-six (88%) had been taking furosemide, and 
26 (50%) had been taking spironolactone. All 
patients had orthopnea, rales at the base of both 
lungs, edema of the extremities and jugular venous 
distension defined as JVP > 10 cm H2O. Mean 
left ventricular (LV) ejection fraction was 42.5 ± 
± 10.5%, mean LV diastolic diameter was 63.7 ± 
± 10.5 mm and mean diameter of the inferior vena 
cava was 23.6 ± 5.3 mm, with reduced respiratory 
movement. The mean serum creatinine level was 
1.12 ± 0.27 mg/mL, mean eGFR was 78.8 ± 12.8 mL/ 
/min/1.73 m2, mean N-terminal prohormone of 
B-type natriuretic peptide was 9,079 ± 7,795 pg/mL 
and mean urine osmolality was 477 ± 167 mOsm/L 
(Table 1).
Urine volume and body weight
Urine volume increased from 1,066 ± 365 mL 
on day 0 to 2,760 ± 956 mL on day 1 (Fig. 3), and 
body weight decreased steadily up to day 7. The 
increase in urine volume and the decrease in body 
weight lessened after day 4. After completion of the 
TLV regimen (day 8), the urine volume decreased 
significantly and body weight increased slightly in 
comparison to measurements on day 7. Daily total 
fluid intakes were less than 24-h urine volume 
minus 500 mL because some of the patients whose 
urine volume was more than 3,500 mL/day could 
not take enough fluid.
Figure 2. Flow diagram showing progress of enrollees 
through phases of the study.
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Change in the plasma concentration  
of TLV (days 1–7)
The plasma TLV concentration increased from 
67.6 ± 30.1 ng/mL on day 1 to 98.3 ± 39.6 ng/mL 
on day 3 (p < 0.01 vs. day 1) to 144.8 ± 44.2 ng/mL 
on day 7 (p < 0.001 vs. day 1), which was approxi-
mately twice the day-1 value (Fig. 4).
Correlation between the urine volume  
and plasma concentration of TLV
Although there was no relation between the 
urine volume and plasma TLV concentration and 
on day 1 (Fig. 5A), the urine volume correlated 
significantly with the plasma TLV concentration 
on days 3 and 7 (r = 0.392, p < 0.01; r = 0.639, 
p < 0.001, respectively) (Fig. 5B, C).
Association between change in the urine 
volume and RAAS activity in the early 
phase of treatment
Change in the urine volume on day 1 cor-
related inversely with PRA and PAC, which are 
indicators of renin–angiotensin–aldosterone sys-
tem (RAAS) activity, after administration of TLV 
(r = −0.618; p < 0.05, r = −0.547; p < 0.05, 
respectively) (Fig. 6A, B).
Discussion
Tolvaptan is an oral aquaretic drug that was 
recognized for insurance reimbursement by the 
Japanese Ministry of Health, Labor and Welfare 
in 2010. It has shown excellent clinical effects in 
ADHF patients with evidence of fluid overload, 
and it broadens our options for the treatment of 
ADHF as an addition to standard furosemide-based 
natriuretic therapy [5–7, 9, 12, 13]. However, ac-
cording to our experience, the clinical response 
to TLV varies between patients, and renal func-
tion, especially renal tubular function, has been 
reported to influence the effects of TLV in the 
kidney [14–16]. Imamura et al. [16] investigated 
the relation between urine osmolality and the 
increase in urine volume of patients treated with 
TLV and reported that the percent change in urine 
osmolality after administration of TLV can predict 
the clinical response.
However, we must also take into consideration 
absorption of the TLV by the digestive system. 
The digestive ducts are usually swollen because of 
systemic congestion arising from decompensated 
heart failure with fluid overload. In addition, these 
days, TLV is generally started as part of the early 
phase of treatment of ADHF with fluid overload 
Table 1. Patient characteristics upon enrollment.
Age [years] 66.4 ± 11.8
Male/female ratio 31/21(60%/40%)
Bodyweight [kg] 68.0 ± 15.5
Heart rate [bpm] 84 ± 18
Systolic blood pressure [mm Hg] 121 ± 15
Diastolic blood pressure [mm Hg] 70 ± 9
Etiology of HF:
Ischemic heart disease 9 (17%)
Dilated cardiomyopathy 19 (37%)
Valvular disease 16 (31%)
Other 8 (15%)
Medical history:











Calcium channel blocker 15 (29%)
Statin 9 (17%)
Symptoms and results of physical examination:
NYHA functional class, I–IV III [III–III]
Killip class, 0–4 3 [2–3]
Extremity edema, 0–4* 3 [2–4]
Jugular venous pressure [cm H2O] 19.3 ± 2.5
Chest X-ray findings:
Cardiothoracic ratio [%] 64 ± 9
Pleural effusion 48 (92%)
Echocardiographic findings:
Left ventricular ejection fraction [%] 42.5 ± 10.5
Left ventricular diastolic diameter [mm] 63.7 ± 10.5
Inferior vena cava [mm] 23.6 ± 5.3
Moderate to severe MR 17 (33%)
TRPG [mm Hg] 37.5 ± 15.5
Laboratory test results:
Serum creatinine [mg/mL] 1.12 ± 0.27
eGFR [mL/min/1.73 m2] 78.8 ± 12.8
Blood urea nitrogen [mg/mL] 28.0 ± 11.8
Serum sodium [mEq/L] 138.2 ± 4.9
Serum potassium [mEq/L] 4.2 ± 0.7
Total bilirubin [mg/mL] 1.2 ± 1.1
NT-proBNP [pg/mL] 9079 ± 7795
Urine osmolality [mOsm/L] 477 ± 167
*0 — none, 4 — severe; data are shown as mean ± standard devia-
tion (SD), n [%] or median [Q1–Q3] values; ACE-I — angiotensin 
converting enzyme inhibitor; ARB — angiotensin receptor blocker; 
eGFR — estimated glomerular filtration rate; HF — heart failure; 
MR — mitral valve regurgitation; NT-proBNP — N-terminal of the 
prohormone B-type natriuretic peptide; NYHA — New York Heart 
Association; TRPG — tricuspid regurgitation pressure gradient
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Figure 3. 24-h urine volume, total fluid intake and change in body weight over the course of the study (days 0–8). Note 
that values were based on the next day’s measurements, e.g., 24-h urine volume shown for day 1 was actually deter-
mined in the morning of day 2. The graph clearly depicts the significant increase in urine volume and decrease in body 
weight after the addition of tolvaptan and that these clinical effects continued until the tolvaptan was stopped on day 7.
Figure 4. Change in the plasma tolvaptan concentration over days 0–7. Note that the plasma tolvaptan concentration 
doubled by the end of the 7-day administration.
rather than the late phase of treatment [9, 13]. Our 
hypothesis is that patients’ digestive ducts remain 
swollen, which affects the absorption of TLV and 
results in various plasma concentrations of the 
drug, accounting for the various clinical effects we 
see in patients with ADHF even though they have 
all been given the same dose of TLV.
Change in the plasma TLV concentration 
over a 7-day treatment
In our study patients, the plasma TLV concen-
tration was 67.6 ± 30.1 ng/mL on day 1, 98.3 ± 
± 39.6 ng/mL on day 3, and 144.8 ± 44.2 ng/mL on 
day 7 (Fig. 4). The reported peak plasma concentra-
tion of TLV in healthy subjects with no swelling 
of digestive ducts was 135 ± 53 ng/mL after oral 
administration of 7.5 mg TLV [11]. This concentra-
tion was higher than concentrations in our study 
patients, probably because of the higher dose of 
TLV administered and the absence of digestive sys-
tem swelling. The previously reported plasma con-
centration of TLV in patients with decompensated 
heart failure was 92.47 ± 53.58 ng/mL on day 1 
4 h after oral administration of 7.5 mg TLV and 
126.04 ± 40.90 ng/mL on day 7 [10]. The plasma 
concentration on day 1 was higher than that in our 
patients probably because there was no evidence of 
fluid overload in the previously reported patients. 
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The plasma TLV concentration on day 7 was lower 
than that in our patients because digestive system 
swelling in our patients was greatly reduced by the 
intensive diuretic therapy. The change in mean 
body weight of the previously reported patients 
over 7 days (−1.5 kg) was less than that of our 
patients (−5.5 kg). Due to the fact that there was 
little change in serum osmolality of our patients 
(from 288.9 ± 11.5 mOsm/kg×H2O on day 0 to 
291.5 ± 10.5 mOsm/kg×H2O on day 1 to 291.69 ± 
± 7.0 mOsm/kg×H2O on day 3 and 288.7 ± 8.6 mOsm/ 
/kg×H2O on day 7), hemoconcentration was not 
seen in our patients. Thus, the increase in the plas-
ma TLV concentration can be explained by improved 
absorbance due to the reduced digestive system 
swelling achieved with diuretic administration.
Figure 5. Relations between the urine volume and plasma tolvaptan concentration on day 1 (A), day 3 (B) and day 7 
(C). No relation was observed on day 1, but correlation was noted on day 3 (r = 0.392, p < 0.01) and day 7 (r = 0.639, 
p < 0.001).
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RAAS activity and the clinical effect of TLV 
during early phase treatment
In the late phase of treatment (days 3 and 7) 
for ADHF, the clinical effect of TLV was shown to 
correlate with the plasma concentration of TLV. 
This was not true during the early phase of treat-
ment (day 1), and then PRA and PAC correlated 
inversely with the change in urine volume. Neu-
rohumoral factors including RAAS factors increase 
fluid retention [17]. Angiotensin-II, in particular, 
increases vasopressin, which weakens the effect 
of TLV somewhat, and aldosterone, which is the 
final product of the RAAS, increases retention of 
sodium and water in the renal tubules and is thus 
thought to act against the effects of TLV [18–20]. 
Neither carperitide nor any inotropic agent that 
would enhance RAAS activity in patients with 
ADHF was used in this study. Therefore, RAAS 
activity, which is usually observed in patients 
with ADHF even though they have been given 
RAAS inhibitors, probably inhibited the effect of 
TLV. It is natural to assume that inhibition of the 
RAAS in the early phase of treatment for ADHF 
enhances the clinical effects of TLV, despite 
previously reported negative results of standard 
diuretic therapy [21–24]. Futher investigations 
of relationship between clinical effect of TLV and 
medications which affect the RAAS activities are 
warranted.
Safety of routine use of low-dose  
TLV in early phase treatment
Some clinical investigators have reported 
the safety and efficacy of immediate use of TLV 
for ADHF [9, 13]. In our study, we used 7.5 mg 
of TLV during the early phase of treatment for 92 
decompensated heart failure patients who showed 
fluid overload after intravenous administration of 
40 mg furosemide. Adverse effects were observed 
in 4 patients, i.e. hypernatremia (serum sodium 
> 146 mEq/mL), but none of them had clinical 
symptoms of hypernatremia. In addition, we with-
drew from administering TLV in 36 patients due to 
the disappearance of evidence of fluid overload in 
fewer than 7 days. Thus, we believe 7.5 mg TLV can 
be used safely and effectively in the early phase of 
Figure 6. Relations between urine volume and plasma aldosterone concentration (PAC) (A) and plasma renin activity 
(PRA) (B) on day 1. Urine volume after addition of tolvaptan correlated inversely with PAC (r = –0.547, p < 0.05) and 
PRA (r = –0.618, p < 0.05).
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treatment of ADHF patients with fluid overload and 
whose urine volume is less than 1,500 mL/day after 
intravenous administration of 40 mg furosemide.
Limitations of the study
Limitations of our study that may have influ-
enced applicability of our results are as follows. 
First, we did not directly observe changes in swell-
ing of digestive ducts or of the absorbance of TLV 
during the week of TLV administration. Second, it 
is possible that the RAAS had a confounding effect 
on the urine volume. Third, we excluded patients 
with low cardiac output on the basis of hypoten-
sion rather than invasive measurement of cardiac 
output. For these reasons, our study findings need 
to be further explored.
Conclusions
In this clinical study, we found that the plasma 
TLV concentration increased during treatment and 
correlated with the clinical effects in the late phase 
of treatment but not in the early phase, which sug-
gested that the effect of TLV has a possibility to be 
inhibited by RAAS activity.
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